text:
Tom Brady and Gisele Bundchen welcomed a new addition to their family this week. Daughter Vivian Lake was born at the couple's home on Wednesday, the supermodel announced on her Facebook page.
"We feel so lucky to have been able to experience the miracle of birth once again and are forever grateful for the opportunity to be the parents of another little angel," the statement reads. "Vivian Lake was born at home on Dec. 5. She is healthy and full of life. Thank you all for your support and well wishes."
Vivian is the couple's second child together and first daughter. She joins older brother Benjamin Rein, who turns 3 on Saturday, as well as 5-year-old John, Brady's son from a previous relationship with actress Bridget Moynahan.
Brady, 35, and Bundchen, 32, have been married for three years.


text: Emerging Therapies, Risk Factors and Other MS Research News from American Academy of Neurology Meeting April 10, 2013 Over 12,000 neurologists and other researchers convened at the American Academy of Neurology's (AAN) annual meeting in San Diego in March to share progress in understanding and treating neurological diseases like MS. In most cases, studies presented are considered preliminary. Many of the results will be analyzed more thoroughly, and usually published in peer-reviewed science and medical journals. Confidence in a study's findings grows when it is repeated by others, with similar results. Read blogs from the AAN meeting Read scientific summaries (abstracts) on the AAN's Website Here are a few highlights from more than 500 MS-related presentations focusing on stopping MS, restoring function, and ending MS forever. STOPPING MS Many studies were presented showing continued benefit and safety of available therapies, and additional findings from therapies proceeding through the development pipeline. Other studies looked at factors that may drive MS progression and relapses, opening possibilities for stopping MS in its tracks. Emerging Therapies Amiloride in progressive MS: This oral blood pressure medicine was tested in a small study of 14 people with primary progressive MS because it had been shown previously to have nerve-protecting (neuroprotective) properties. Dr. Tarunya Arun of Oxford University, with colleagues in the UK and Netherlands, reported that after 3 years, treatment with amiloride resulted in a reduction of brain shrinkage associated with progressive disease, compared to what was experienced before treatment. Further testing is getting underway in a larger study in the UK, which the National MS Society is helping to support through the UK MS Society. (Abstract S31.002) Large trial in progressive MS: A poster presentation by Dr. David Miller of University College London and an international team suggested that good progress is being made in a large trial of Gilenya® being supported by Novartis Pharmaceuticals Corporation. The study involves more than 1000 participants with primary-progressive MS, and it's designed to determine if Gilenya can slow down MS disability compared to inactive placebo after 3 to 5 years of treatment. This is one of several large studies like this underway in progressive MS. (Abstract P07.116) New form of existing therapy for relapsing MS: Dr. Peter Calabresi of Johns Hopkins University presented results of an international, phase 3 trial of peginterferon beta-1a in relapsing MS, a new form of Avonex® designed to stay in the body longer than the standard form. The results over one year suggest peginterferon injected under the skin every two or four weeks was effective in reducing relapse rates and also reduced the risk of progression of disability. This study is continuing into a second year. Trial sponsor Biogen Idec has announced plans to apply for regulatory approval in 2013. (Abstract S31.006) Copaxone® in fewer doses: Dr. Omar Khan of Wayne State University, Michigan, presented results of a one-year phase 3 trial supported by Teva Pharmaceuticals suggesting that under-the-skin injections of twice the standard dose of Copaxone, taken three times per week, were effective in reducing relapses and MRI-detected disease activity, and revealed no unexpected safety issues. (Abstract S01.005) Switching therapies: A large study in France called ENIGM tracked the impact of switching from therapy with Tysabri® to Gilenya.® Among 200 people who switched after an average of 30 months on Tysabri, there was a "washout" interval of 3 to 6 months in which no therapy was given, during which 32% experienced a relapse. The researchers concluded that switching increases the likelihood of disease reactivation, and that the washout period should not be longer than 3 months. (Abstract 41.002) More results on Tecfidera™: An evaluation of two phase 3 trials of oral dimethyl fumarate (Tecfidera, Biogen Idec), recently approved by the FDA for relapsing MS, suggested that the treatment began to take full effect against MS disease activity after 3 months' use, and the effect was sustained over the two years of the trials. (Abstract S41.005) Extension studies: Several presentations focused on results from extension phases of completed clinical trials in relapsing-remitting MS, including the following. These often involve open-label periods where participants who were on placebo during the original trial are switched to active treatment and others participants continue on therapy and are evaluated for a period of time. Extension of a phase 2 study of infrequent infusions of ocrelizumab (Hoffmann-La Roche Ltd.) showed continued effectiveness at week 144 in most who continued in the study and no new serious adverse events. Ocrelizumab is in further testing for both relapsing and progressive MS. (Abstract S31.004) A one-year extension of a phase 3 study of oral laquinimod (Teva Pharmaceuticals) showed that the risk of disability progression was significantly reduced for those who started on active therapy in the original trial versus those who started on placebo and then switched to therapy during the extension phase. As in the original trial, the most common adverse event was elevated liver enzymes. (Abstract S41.004) A one-year extension of two phase 3 alemtuzumab trials (Genzyme, a Sanofi company and Bayer Healthcare Pharmaceuticals) showed there was a durable benefit against relapses and progression, often without additional IV infusions. Risks continued for adverse events including thyroid disorders and autoimmune disorders, and one person died from sepsis. Alemtuzumab is currently being evaluated by the FDA for marketing approval. (Abstract 41.001) A one-year extension of a phase 2 trial of daclizumab high-yield process (DAC HYP, Biogen Idec and Abbott Biotherapeutics) showed that monthly under-the-skin injections continued to reduce relapses, MRI disease activity, and disease progression. There was one death due to autoimmune hepatitis and the incidence of serious infections, skin events and liver function test abnormalities were similar to those found in the original trial. (Abstract S01.001) Exploring Disease Activity Can vaccinations trigger MS attacks? Dr. Mauricio Farez of Universidad del Salvador, Buenos Aires, Argentina reported on his analysis examining whether common vaccinations are linked to MS. Among his findings, he reported that vaccination against yellow fever may substantially increase the risk of MS relapse, suggesting that someone with MS who is planning a trip to a country where there's increased risk for yellow fever should discuss the risks and benefits of vaccination with an MS doctor. (Abstract S10.001) Sugar and progression: We don't know yet why some people's MS progresses slowly and others experience rapid progression, but a small study from Drs. Wael Richeh, Jesus Lovera and colleagues at Louisiana State University gives food for thought. They asked whether blood sugar is linked to levels of MS disability, and found that people with higher levels of glucose were more likely to have higher levels of disability. This important lead needs more study to prove a role for blood sugar in MS progression. (Abstract P04.130) Genes and kids: Drs. Emmanuelle Waubant and Jennifer Graves at the University of California at San Francisco and collaborators described preliminary results of a gene study in 117 children with MS, showing that one particular gene (rs4648356) was associated with lower rates of relapse, while another (rs11154801) was associated with higher rate of relapses. The study, which requires confirmation, was supported by the National MS Society and the Consortium of MS Centers. (Abstract P05.133) Predictors/Disease Tracking Tools: Tool to track progression: Dr. Nicholas LaRocca of the National MS Society described efforts of the newly formed MS Outcome Assessments Consortium to accelerate development of more effective treatments for MS, particularly for progressive forms of MS. MSOAC is a coalition of industry, academia, patient representatives, regulatory and other government agencies, and the National MS Society. In collaboration with the Critical Path Institute, they will analyze data from completed MS clinical trials and other studies and work with regulatory agencies to qualify a new clinician-reported outcome measure that can be used to more sensitively track the impact of therapy on disease disability and progression for future MS trials. (Abstract S31.001) Predicting who will respond to Copaxone®: Drs. Francisco Quintana, Howard Weiner and team at Harvard's Brigham and Women's Hospital described a study that analyzed serum samples from people with MS who were taking glatiramer acetate (Teva Pharmaceuticals). They were able to find antibody profiles that could detect those who responded to therapy and those who did not. Further work to confirm these findings could lead to a method to know early on whether a person is benefiting from this treatment or not. (Abstract S11.002) RESTORING FUNCTION The broad area of research to restore function encompasses efforts to repair the nervous system and also stimulate recovery of lost function through exercise, rehabilitation and other means. "Rewiring" the brain: Invited speaker Dr. Maria Assunta Rocca of San Raffaele Hospital in Milan, Italy presented compelling data for how the brain reorganizes to adapt to MS damage. In one study, the team looked at the impacts of a 12-week computer-assisted course that focused on training to increase memory and attention. They had previously reported improved attention and executive thinking abilities. Using functional MRI, which allows a real-time glimpse of the brain at work, they also found indicators that brain circuitry and activity had increased in specific areas, which appeared to persist at least 6 months after the training was completed. (Abstract P04.030) Exercise and the brain: A small study from Society-supported scientists Drs. Victoria Leavitt, John DeLuca and others at the Kessler Foundation in New Jersey tested whether aerobic exercise impacts the brain. Using MRI scans and memory tests, they found hints that aerobic exercises (30 minute sessions, 3 times a week, over 3 months) improved memory and increased the volume of the hippocampus, a part of the brain involved with memory and other functions. These preliminary results require additional follow-up. (Abstract P04.034) Exercise and fatigue: German researchers Drs. Stephan Schmidt of Bonn, and Marc Wonneberger of Cologne reported on the impacts of longer-term aerobic exercise to build endurance in people with MS. This study involved 60 people split into two groups: those with fatigue and those without fatigue. Both groups did individualized endurance exercise on treadmills for 12 months. After 6 months of exercise, both groups had improved oxygen consumption, but those who started out with fatigue didn't show improvement in their fatigue scores until 9 months into the program. (Abstract P04.042) Brain power: Researchers from Milan and from Kessler also reported that people with MS with more "brain reserve" (larger brain size) and more "cognitive reserve" (higher levels of cognitive leisure activities when they were in their 20s) were at lower risk for cognitive changes associated with MRI lesions. Even when brain size was accounted for, those with more cognitive reserve appear to have lower risk for cognitive changes. Research is ongoing to see whether enrichment activities can help build cognitive reserve. (Abstract P04.109) CCSVI treatment in MS: First results from a controlled endovascular treatment trial (percutaneous transluminal venous angioplasty) were presented by Drs. Robert Zivadinov, Adnan Siddiqui and the team from State University of New York at Buffalo. In this blinded study, 9 people had the angioplasty and 10 had a sham treatment. At six months, the team did not detect adverse events from the treatment, but also found that it failed to provide sustained improvement in venous outflow. They also found that those whose veins increased in outflow tended to have increased MS disease activity seen on MRI. (Emerging Science Poster P04.273) Prevalence of CCSVI in MS: Dr. Robert Fox, Claude Diaconu and a team at Cleveland Clinic and Case Western Reserve reported preliminary results from a National MS Society-supported study of CCSVI in 61 people with different types of MS and 20 people without MS. They used ultrasound techniques that included technicians trained in CCSVI assessment who were unaware of the participants' disease status. Although changing the interpretation of CCSVI criteria produced substantial differences in the proportion of participants meeting those criteria (20% to 40% of non-MS met criteria versus 21.3% to 36.1% of MS participants), there was no significant difference between the non-MS and MS groups. (Abstract P05.177) ENDING MS FOREVER There were several reports focusing on risk factors that may contribute to making a person more likely to get MS, including recaps of National MS Society-supported studies related to salt and MS immune activity. This line of research could eventually lead to ways to prevent people from getting MS. Dystel Prize: This year's winner of the John Dystel Prize for MS Research, given jointly by the National MS Society and the AAN, was Professor George Ebers of Oxford University, UK. He presented his work on the influences of genes and the environment in relation to who develops MS. Read more Reproduction and risk of MS: Drs. Melinda Magyari, Per Solberg Sorensen and colleagues from the Danish MS Center in Copenhagen looked at potential factors that may account for an increased incidence of MS in women over several decades. Using the Danish MS Registry, which captures info on most people in their country who have MS, they found that pregnancy and childbirth offered significant protection against developing MS, lasting up to 5 years. This and other studies can offer more clues to the influence of hormones and other factors in MS. (Abstract IN8-1.001) Environmental exposures: Drs. Ellen Mowry at Johns Hopkins University, Lisa Barcellos at University of California, Berkeley and colleagues asked a proportion of women enrolled in Kaiser Permanente Northern California health care about their possible exposures to specific environmental factors. They adjusted results for some known risk factors such as genes already known to increase MS risk, vitamin D status, prior mononucleosis, and smoking in order to seek new possible factors. Results, which require further study, show that women exposed to small pets and reptiles may have been protected from developing MS, while those exposed to hair permanent solution may have had increased risk for developing MS. (Abstract P05.138) Avonex is a registered trademark of Biogen Idec Copaxone is a registered trademark of Teva Pharmaceutical Industries Gilenya is a registered trademark of Novartis Tecfidera is a trademark of Biogen Idec Tysabri is a registered trademark of Biogen Idec and Elan Pharmaceuticals

subset: commoncrawl


text:
A couple of Tuesdays ago for Moms and Kids Club we went to Bedford Splash, an extrememly fun waterpark close by. Kinsley had fun "swee-min", and Kaden, being the little daredevil that he is wanted to do all the big kid slides! They had a blast with all their precious little friends and especially loved this turtle!
The other picture is of my little "Storm".
Blastball is now over but was so much fun! Now were on to the next sport - soccer I think! I love being a little - league mom!
19 minutes ago


text:
Nope. I have tried several times through the year. I'm sure they have had things in stock at points, but not much and clearly never for long. The coupon expires in a week and there's nothing available.
Yeah, when they open back up, just email them again, tell them you've been trying to get a hold of someone for a few weeks... they might be nice enough to do it if you really have been trying all year long.
GG just sent out their coupon codes to PGMs
Yes, mine process automatically yesterday.
Page created in 0.064 seconds with 18 queries.


text: I recently did some hard work in a chess tutor program. It is an interesting atmosphere for young kids to learn chess. It has error detection, suggestion making abilities, and also can play against a human quite well. It was an interesting venture. Now I am looking to expand my skills and play big!


text:
One thing that's hard about blogging is that I struggle to organize my thoughts into just one topic to write about. Maybe I should make a list: my job, my plans, my husband and his plans, our garden, my novel, my nebulous idea that might just become a novel, my endless blood sugar roller coaster, my new church calling, the quirky but great movie I saw last night, and on and on. And there's just so much to life. I used to write for several hours a day and I always felt there was never enough time or paper or words to do justice to all that is out there (or in my head, whichever the case may be).
So how can I update you on what has happened since I last wrote? I think I have never had so much worry in all of my life, but I have also have never felt so strongly the Lord's love for his children. "Love for his children" sounds like a generic statement, but it isn't really. It's such a specific thing.
There was a day last week when I had to go fill one of my presciptions and we had to make the choice between getting the medicine and paying our car insurance. Our policy had expired and if we didn't renew it, we simply wouldn't be able to drive our car anymore. Not that it would be the end of the world, but it was a hard decision to make. I felt like I was being selfish, worrying about myself more than "us," but we made our minds and went to Rite Aid.
When I went to pick up my medicine, the woman behind the counter scanned the paper envelope with the medicine in it and said, "That will be eight dollars."
I looked up in surprise, half-irritated that she had scanned the wrong thing. My medicine cost more than ten times that amount. I said, "What? Really?"
"Um, yes," she said, looking at me curiously, "eight dollars. You are Jessica Robbins?"
I nodded, but didn't believe. "Eight?" I said incredulously, "Are you sure? That's metformin?"
"Yes." she said, "Another pharmacy is having a sale and this is a price match. . . You do want it, don't you?"
I almost started crying right there on the spot. I just laughed and pulled out eight dollars. "Of course I want it!"
So I went running out into the parking lot and we went straight to the car insurance place to renew our policy.
I don't know if it all sounds as miraculous as it was, but I had been so stressed about all my stupid expenses, up all night sick with worry so many nights in a row, trying to figure out some way to make it happen. And just like that, the Lord took it right out of my hands.
And that's just one miracle of so many I've seen these past weeks. It hasn't been a picnic trying to hold down a job when my blood sugar skyrockets and plummets several times a day regardless of how I eat. One day, I was afraid to move because my blood sugar was so low that I was seeing flashes of white. I was at work being trained and right in that desperate moment, some woman showed up and walked right up to me with a plate in her hand. On the plate were samples of highly sugary energy bars. The sample shot my blood sugar up to where it needed to be for me to get through the shift. I knew without a doubt that someone was watching over me.
It just amazes me how aware of my life my Savior is. I don't think there's any part of it that He doesn't care about.
Well, lest I worry anyone, the semester has just ended for Paul and me, my job ends tomorrow, and Paul's job starts as soon as possible. My dear love has pulled off lovely straight A's in spite of all the stress and he's been applying for jobs like crazy. He's got to find something that will give him enough hours and a high enough wage to support me because I'm not working again until I can get my condition under control. (Frankly, I'm a useless worker these days.) We made a killing at the textbook buyback and between that and a yard sale, we will happily be able to pay our rent for May! I'm sure something good will happen between now and my next metformin refill so we'll be able to get that too.
After all, we're not in this thing alone.
Thursday, April 24, 2008
My miracles.
One thing that's hard about blogging is that I struggle to organize my thoughts into just one topic to write about. Maybe I should make a list: my job, my plans, my husband and his plans, our garden, my novel, my nebulous idea that might just become a novel, my endless blood sugar roller coaster, my new church calling, the quirky but great movie I saw last night, and on and on. And there's just so much to life. I used to write for several hours a day and I always felt there was never enough time or paper or words to do justice to all that is out there (or in my head, whichever the case may be).
Posted by Jessio at 8:43 PM
Friday, April 11, 2008
Honest for once.
So, here is another day of the Chronicles of Jessio. A blog with that title makes me want to write about exciting, interesting, silly, or hilarious things. It seems that all my stress has made my mind become very serious and when I open the laptop, I can't think of anything that would entertain anyone. It has all become almost a blur of frustrations and days stacked upon days in which nothing particulary improves.
Do I sound like a pessimist? Well, for once I just want to be honest! I am sick and each day is difficult and I can never stop worrying about how we'll pay for my meds, for my doctor visits, for my test strips when we have no insurance and no way to get it. But no matter how many times I have considered stopping my treatment (which is almost every day) I come back to the conclusion that I am too afraid of what will happen if I do. I am terrified of those high blood sugar levels and endless nausea and feeling like I'm starving to death. I don't want it all back, but I feel like it has all been a trade for different miseries.
But I always have Paul and he is more nurturing and sweet than I could have dreamed. He loves me so much and is patient every day with me. We only have about two weeks now to the end of school and then he will start working again. Cross your fingers that he will be able to get medical insurance. There are a few different jobs he's applying for and he's still looking for others too so he can find something really good. He has done very well this semester and has shining A's to prove it. I'm proud of him for working hard in school and improving his chances of being accepted to graduate schools this coming fall. Won't life be swell when he has a PhD and medical insurance is no longer an issue?
I am strained and frustrated and exhausted, but I'm sure that things will somehow work out. I still remember what I learned in Primary.
"Why did we come to earth, children?"
"To be tried and tested!"
"And why is that important?"
"To see if we really love Heavenly Father."
Well, I do love him and I hope all this will somehow show him that I do. I don't know if honesty in blogging will make for a very popular blog. (People generally seem to like a lot pictures and humor.) But I don't care. This is my life right now and while I'm living it, I wanted to write about it.
Posted by Jessio at 9:44 AM
Sunday, April 6, 2008
A Conference Thought.
Well, Conference is over! I looked forward to it with excitement and now it has passed so quickly. One of the last talks, by M. Russell Ballard, was about young mothers and ways that we can all help them. It was a really good talk and I was struck by one thing he said. I didn't write down the exact quote, but it was something along these lines: A woman who is not being nourished herself has much less to give to her children. He talked about mothers finding time alone to cultivate talents and grow.
I'm not a mother yet. That's one adventure that hasn't hit me yet, but I like the principle. Giving to others is wonderful and service undoubtedly builds love. But when your personal needs are not being met, you cannot be your best self to give to others. It's hard for a starving person to think about anything but getting the food they need. Similarly, if your life does not fulfill all of your personal and emotional needs and dreams, you will not be able to give your full attention to the people in your own life. You won't be the best version of yourself.
So, of course, this all applies rather directly to me. There are things I love to do that I NEVER do. Why don't I draw anymore? Why don't I sing? Those things I love and they refresh me and help me face life in a more relaxed way. It's stupid to not set aside a little time each day to do these fulfilling things. Then I can be a better happier me and it will be easier for me to care about others and feel satisfied. How can you spread happiness if you don't have it?
Posted by Jessio at 4:34 PM
Saturday, April 5, 2008
The power of one life.
Yesterday, I went to the funeral of a little cousin of mine. Her name was Hunter Watkins and the funeral was quite an emotional event. She had been ill for a very long time and I didn't expect to be as affected as I was by the funeral.
As I walked into the viewing, I was reminded forcefully of my own sister's funeral fourteen years ago. I was eight years old at the time. The thing that stands out in my memory of that day was how cold her fingers felt as she lay in the casket. I reached in to touch her and I had the distinct impression that the cold body I was touching was not her. The body was a thing and she was separate from it. I understood that at the time, but it was not until later that I began to comprehend the significance of it.
I looked down at Hunter's body and she looked beautiful in a white dress. Her hair was curled and placed perfectly and she looked just like a sleeping princess. I was surprised how much she reminded me of her sister Lacey. I hugged her parents and didn't know what to say to them. I sat down and gazed at the casket in wonder. In my mind, it was easy to see her sitting up and looking around, beautiful and completely whole. No more wheel chair. No more disease and suffering. I felt so strongly the power of the atonement in that moment and I thought back.
My sister was tormented as well by sickness and pain and surgeries. Her poor heart had to work so hard with two holes in it. She would begin crying anytime someone touched her feet because she knew that usually meant a shot. I think about the courage of these children who come to earth knowing they will suffer. Children like Sheridan and Hunter endure these things willingly because they know that they can help the rest of us. I know I have been changed forever by the experiences I had as a small child with my sister Sheridan.
Perhaps the hardest thing about the funeral was seeing Hunter's sisters weep as the casket was closed. I wondered if they felt what I felt as a little girl when my sister's casket was closed. Do they know that the body they placed in the earth is not the sister they cared for and loved? Hunter is separate and happy and will come back to her body again someday. I believe that.
I have cause to ponder on the purpose of one life. I think we sometimes forget the power that one life can have. And we all have this power in whatever our situation. No one was placed on this earth alone and it is significant to consider the people within my own sphere of influence. I feel inspired to reach out to others, to do better at thinking of them and finding ways to show love. Isn't life all about becoming like the Savior? And he didn't withold his love from anyone.
Posted by Jessio at 11:23 AM


text:
As was reported Friday by Newsweek/ The Daily Beast, two United States Citizenship and Immigration Services (USCIS) District Offices have confirmed that alien relative petitions and green card applications filed by married same-sex couples will not be denied. Instead, final decisions on these applications will be held in abeyance, i.e. put on hold. This historic first seems to be directly linked to the Obama administration's change of position on DOMA announced on February 23. The DOMA Project welcomes the new and exciting potential this presents for married gay and lesbian couples to obtain legal status and prevent deportations of the foreign partner. However, in this new and rapidly changing legal environment, we urge attorneys and binational couples to proceed with an abundance of caution.
The significance of the "abeyance" policy is two-fold: first, it means that petitions and applications that normally would have been denied because of DOMA, will now remain in "pending" status, and second, this status will give protection and benefits to the applicant for an indefinite period. The "abeyance" policy, it is presumed, will put these cases on hold while the ultimate fate of DOMA is determined by a decision of the Supreme Court or through repeal by Congress.
This tremendous news comes after months of advocacy by national immigration law and policy groups, LGBT organizations and advocates including The DOMA Project. While The DOMA Project has focused primarily on stopping deportations, we have also engaged in wide-ranging advocacy and provided legal representation in related cases where couples are fighting separation or exile.
As readers of this site know, since July 2010 we have filed more than a dozen alien relative petitions on behalf of gay or lesbian American citizens for their spouses as part of our Stop The Deportations campaign. Our campaign has been successful in slowing and stopping several deportations through a combination of legal strategies and aggressive advocacy efforts, including reaching out to members of Congress and working closely with executive branch agencies.
In the coming days and weeks, the attorneys at Masliah & Soloway, who launched The DOMA Project last year, will be filing green card cases on carefully chosen behalf of several same-sex binational couples who are not currently facing deportation proceedings. We have been working for months with hundreds of binational couples in an effort to determine which couples are in the best position to file green card petitions and applications. For some couples, we believe that time is now.
This latest evolution in our strategy to aggressively fight for binational couples is the culmination of an 18-year long commitment by our law firm⎯led by two gay immigrants⎯to fight for an end to discrimination against lesbian and gay binational couples.
What does this mean for an estimated 36,000 binational couples?
Some married gay and lesbian binational couples will now have an opportunity to take a major leap toward full equality under our nation's immigration laws. However, it is important to remember that DOMA is still the law of the land and despite this tremendous news, filing green card applications in this uncertain environment could result in a foreign spouse being placed in removal (deportation) proceedings. For that reason, no couple should make a move toward marrying or filing on the basis of the marriage without first consulting an immigration attorney with specific expertise in both LGBT immigration issues and the developing landscape of DOMA.
Generally, the risk all couples face if they chose to file is that they may ultimately be placed into removal proceedings. Because the announced policy is one that was developed at the discretion of the District Directors of the offices involved, it is not yet known whether this policy will be extended nationally nor whether it may be changed in the future. Again, it bears repetition that couples and their attorneys must proceed with extreme caution.
This development will have the greatest impact on two groups of couples:
1. Married gay and lesbian couples where the foreign spouse lawfully entered the United States but is now an "overstay" and without lawful status. For these couples, the filing of an alien relative petition and application for adjustment of status to permanent resident should automatically give temporary lawful status to the foreign spouse for the duration of the period that the case is pending. If these applications are in fact held in abeyance until DOMA's final demise, this could mean that couples who have wrestled for years with the nightmare of deportation, separation and instability caused by a lack of lawful status may now be on the verge of a new reality. The foreign spouse will not only receive (temporary) lawful status, but also employment authorization and potentially other benefits, as long as they have a pending green card application. Unfortunately, despite the temptation that this will present to many couples, for many it will be better to wait until there is greater certainty about this policy and the future of DOMA.
2. Married gay and lesbian couples who are already facing removal (deportation) proceedings. It is now likely that we will be able to stop virtually all deportation proceedings involving married gay and lesbian couples who have filed green card petitions/applications and who are, but for DOMA, otherwise eligible to receive a green card based on their marriage. Even couples in removal (deportation) proceedings must proceed cautiously when considering whether to marry and file a green card petition/application based on that marriage. However, unlike those who are not in proceedings, the risk of deportation is very real, and the likelihood is that this new development will provide protection to almost every couple facing deportation, if they are currently in proceedings.
There is light at the end of the tunnel for binational couples. The individual stories of binational couples suffering separation, exile or the threat of deportation continue to be our most important weapon in the fight against DOMA. There is still a long road ahead before we achieve full equality and we cannot be complacent.
Please contact us at stopthedeportations [at] gmail.com if you want to get involved in our work or if you have any questions about the new "abeyance" policy.
[Update: March 29, 2011: It now seems certain that the temporary national abeyance policy announced March 28, 2011 will end shortly. Government attorneys working on final guidance suggest that USCIS will retain case-by-case discretion but will not be permitted to put on hold indefinitely all green card applications filed by married gay and lesbian couples. The DOMA Project will continue to advocate for a uniform abeyance policy, for the interim period while DOMA continues to be enforced.]


text:
How can we help you?
We matched that to:
How do I view my online statements?
Viewing Online Statements
Log in to EasyWeb, then select Statements & Documents in the left-hand navigation. All your accounts that have been switched to Online Statements are listed here. This will show the available statement(s).
If you're not already registered for EasyWeb Internet banking, you can register online for internet banking that's secure, convenient and easy. You'll be able to access Online Statements and many other useful services, like web bill payment.
Thank you.
Please note that the answers to the questions are for information purposes only for the products discussed. Individual circumstances may vary. In case of discrepancy, the documentation prevails.


text:
I posted this week on the BFBS Facebook page my belief that the breastfeeding covers have done more to hurt the NIP (Nursing in Public) cause than help it. Before I go on, I know plenty of people that use the covers. I am glad that they are breastfeeding and not giving their baby a bottle of formula. I realize that for some women, it's all they can do to actually be out in public breastfeeding, even with a cover. I've had moms come to childbirth class reunions and wear the covers and say, "Screw you, Donna, I'm using it!" I don't really care. I really don't. I love them for that. I really don't care about the individual use of the covers. I am, however, concerned about the perpetual use -- the expectation that all breastfeeding women should cover -- that concerns me. I think women are being told to cover up more often because of the covers.
We all know that the breasts are totally sexualized in the United States. Breasts are sexual, like it or not. I'm not going to tell you to not think of breasts that way. But it is OK that they have a function too. People -- men and women -- are uncomfortable with this. We see breasts and cleavage hanging out everywhere we go, but using them in a functional way, to nourish a baby through sucking at the breast, makes just about everyone uncomfortable. We want rights and we demand that everyone not sexualize the breast, but then we wear the covers which, in effect, hides their function.
Several people commented on the Facebook page that they were concerned about men, teenagers, and children being exposed to breastfeeding. This perpetuates the problem, that we are not allowing them to be around breastfeeding. I've seen people make comments that "Everyone knows what's going on under there," but that's not necessarily true. A lot of people have no idea what's going on under there because they've never witnessed a woman breastfeeding, especially if everyone is using these covers! Children don't know what you are doing. Teenagers probably don't know either. Even if they do, it is obvious that you are hiding it, so by the very nature of the hiding behavior, it must be shameful or embarrassing. They do not learn that breasts serve another purpose besides sexual excitement.
I was at the park with a friend a couple of years ago who had a nursing baby. My children were back and forth from the picnic table, but my son (then about 12), was hanging out at the table with us. She always breastfed anywhere, so I was surprised when she asked if she should cover or go sit in her car. For a split second, I thought maybe she should cover. I immediately told her of course not. Feed her baby. She did, and Daymon didn't even bat an eye. He didn't try to look away or look uncomfortable. I think he was already aware that breasts have a function and the baby needed to nurse.
Likewise, my girls have never acted weird about it either. They see women breastfeeding in our house all the time. They don't look away or act embarrassed. It's just how women feed their babies. But I don't act weird about it -- or even draw attention to it -- and so they don't either. Occasionally I will have someone using a cover and at least one of my girls will stare. She'll look confused, knowing there was a baby in her lap before, but now they are all covered up. She has no idea she is feeding her baby.
I am happy you are choosing to breastfeed. I just want women to have confidence in themselves to breastfeed in public. There are so many ways to wear your clothing. You do not have to be immodest to not use a cover. I believe that our children -- and husbands -- will be more excepting of breastfeeding and it will become accepted, not shameful, if women will just casually nurse their babies without hiding. People often say they are covering because it makes them more comfortable, and this is what makes me sad -- that they are made to feel uncomfortable in our society.
I realize that you may sweat bullets when you have to nurse in public. It is stressful for some women. I don't want women to feel like they are damned if they do and damned if they don't. All I am trying to get across is that if you feel like you could easily handle nursing in public without a cover, from a cultural perspective, I think it's good for people to see women proudly breastfeeding. If you just can't get over it, then by all means, use a cover, knowing you are doing the best you can. I promise I won't say a single thing to you if I see you using a cover!
Before I let you go, I wanted to show you the bathroom my students -- and everyone else that comes to my house -- uses. It is devoted to pregnancy, birth, and breastfeeding. It's gorgeous! For some, it's probably their only exposure to breastfeeding! Enjoy. If you come to my house, don't forget to ask to use my bathroom.
"Breastfeeding is a mother's gift to herself, her child, and the earth."


text:
I do want to let you all know that Mom and I will be on The Stupid Cancer Show on Monday, May 2. The 'Stupid Cancer' Show is a radio show hosted by Matthew Zachary, CEO and Founder of the I'm Too Young For This! Cancer Foundation, and Lisa Bernhard, Executive VP and Media Development for the Foundation. The show is entitled, "Parents of Young Patients." I will be on air as the Survivor Spotlight, and Mom will be one of the two guests on the show. It's going to be a wonderful show, so please mark your calendars and tune in! The link is here.
I'll more than likely post again later on in the week. I have more to tell! All good things; I promise. :-)
As always, I wish you all love, happiness, and -- most importantly -- good health.


text:
Elan Pharmaceuticals Leverages Infosys Scientific Innovation Solution for New Research Informatics System
Fremont, CA – February 1, 2010
Infosys Technologies Limited (NASDAQ: INFY) today announced that it will design and implement the Research Informatics System (RISe) at Elan Pharmaceuticals, Inc (NYSE: ELN), a leading biotechnology company, to accelerate discovery research using a path-breaking co-creation engagement model that leverages Infosys' existing intellectual property in this field.
"We are confident that partnering and collaborating with Infosys will create a comprehensive informatics platform for our discovery research needs," said Ajay Shah, Director – Research Informatics, Elan Pharmaceuticals. "We selected Infosys after a competitive Proof-of-Concept phase during which they fully established their credentials and investments in this changing field of discovery research, and demonstrated flexibility and maturity in terms of rapid application development using Agile and Scrum methodologies. With Infosys' solution and engagement model, Elan will be able to lower costs for scientific operation and facilitate innovation.
As Elan's informatics system, RISe will leverage Infosys' Scientific Innovation Solution for knowledge collaboration. Novel ways to unlock disparate data spread across in-house research labs and other commercial or public sources will be presented to scientists in context of their research needs. This will result in, among other things, a customized registry, and inventory and a workflow management system for biological entities.
Elan and its research partners could realize significant gains in research productivity by focused and efficient selection of candidate drugs or biologics with the new RISe. Linking silos of heterogeneous data will not only contribute to a more effective selection process of biologics but could also reduce time to validate them clinically. Furthermore, the new system will reduce time spent on registering and experimenting with bio-entities, increase collaboration, and reduce chances of downstream failure.
Future versions of the software may enable integration of RISe with electronic lab notebook and analytical dashboards which will enable more efficient research knowledge management.
The co-creation engagement model enables Infosys to retain ownership of co-developed IP as part of the implementation. Relevant components of this reference implementation can be reused or repurposed by Infosys to deliver faster business benefits at other Life Sciences organizations.
"Elan's vision to create a scalable research informatics system for scientists to collaborate better, dovetails perfectly with our investments in solutions that improve scientific innovation and our efforts to streamline discovery research," said R Arun Kumar, head of Infosys' Global Life Sciences Practice, Infosys Technologies.More information can be found at Infosys' Scientific Innovation Solution website: http://www.infosys.com/industries/life-sciences/industry-offerings/pages/scientific-innovation-solution.html
Elan Corporation, plc is a neuroscience-based biotechnology company committed to making a difference in the lives of patients and their families by dedicating itself to bringing innovations in science to fill significant unmet medical needs that continue to exist around the world. Elan shares trade on the New York and Irish Stock Exchanges. For additional information about the company, please visit http://www.elan.com.
Infosys (NASDAQ: INFY) defines, designs and delivers IT-enabled business solutions that help Global 2000 companies win in a Flat World. These solutions focus on providing strategic differentiation and operational superiority to clients. With Infosys, clients are assured of a transparent business partner, world-class processes, speed of execution and the power to stretch their IT budget by leveraging the Global Delivery Model that Infosys pioneered. Infosys has over 109,000 employees in over 50 offices worldwide. Infosys is part of the NASDAQ-100 Index and The Global Dow. For more information, visit www.infosys.com.
Statements in connection with this release may include forward-looking statements within the meaning of US Securities laws intended to qualify for the "safe harbor" under the Private Securities Litigation Reform Act. These forward-looking statements are subject to risks and uncertainties including those described in our SEC filings available at www.sec.gov Opens in new window including our Annual Report on Form 20-F for the year ended March 31, 2009, and our other recent filings, and actual results may differ materially from those projected by forward-looking statements. We may make additional written and oral forward-looking statements but do not undertake, and disclaim any obligation, to update them.
For further information, please contact: email@example.com


text:
The best way to reduce risk for osteoporosis — a thinning and weakening of the bones — seems to be the subject of ongoing debate. This month brought a fresh round of questions after a report published in the New England Journal of Medicine suggested that vitamin D is the key ingredient to preventing and reducing broken bones. Dr. Sonali Khandelwal, a rheumatologist and co-director of the Osteoporosis Center at Chicago's Rush University Medical Center, gave us some answers.
Q: A bone mineral density test screens for osteoporosis. How often should women get tested? It seems like there's little consensus.
A: For women going through menopause, we recommend to get one as a baseline, then follow up every two years. Women who are premenopausal or have risk factors like malnutrition or a family history of osteoporosis should do the screening earlier. The frequency is a little subjective ... but we do know thatpost-menopause seems to be the time when bone density will decline the most.
Q: How are test scores reported?
A: As T-scores, which compare the patient's bone density with that of a healthy young woman. A T-score of -1.0 or higher is normal. between -1.1 and -2.49 indicates moderate thinning — or osteopenia — and T-scores of -2.5 or less indicate osteoporosis.
Q: So what do you make about this analysis of multiple studies, showing that those who took 800 units daily of vitamin D were 30 percent less likely to suffer fractures than those who didn't?
A: There's a lot of controversy regarding adequate amounts of vitamin D. My current recommendations, based on NOF (National Osteoporosis Foundation) recommendations, are that post-menopausal women need 800 to1,000 units of vitamin D daily, while pre-menopausal need 400-800 units. Vitamin D is vital for bone health, calcium absorption and muscle strengthening.
Q: So, is the key vitamin D, not calcium? Should everyone be on supplements?
A: It's hard to make blanket statements ... but in general, yes. Vitamin D — unlike calcium — is difficult to get from diet alone. It's needed for the body to absorb calcium and thus an integral part of bone health.
Q: Have I been wasting my time, chomping on calcium chews all these years?
A: No, that is wonderful. But you still need the vitamin D.
Q: If you've been on Fosamax and other biophosphates, is it important for your doctor to give you an occasional drug holiday?
A: Of late, the idea of taking a break has become more important. ... We know that over the long term, these drugs can slow bone remodeling, meaning that the overall bone turnover is reduced or even stopped, thus making individuals at risk for atypical fractures. When to pursue a drug holiday or continue therapy becomes a case-by-case scenario, depending on an individual patient. ... Individuals who have been on long-term therapy or for whom there is a concern, we often use Teriparatide, the only FDA-approved osteo-formative agent.
Q: If you do take a break, how long before you resume the drugs again?
A: Again, there's no consensus, but resuming therapy would be based on repeat bone-density measurements and evaluation of the patient's risk factors.
Q: All these concerns seem to only afflict women. Do men have to worry about thinning bones?
A: About 2 million men are affected with osteoporosis, compared to 8 million women, according to the National Osteoporosis Foundation. Screening is usually started at age 70 for men, however earlier screening should be done in men who have risk factors, including rheumatologic illnesses and certain cancers.
Q: We know if you don't change the oil, your car will break down sooner. So what is the equivalent of car maintenance so bones don't fall apart?
A: First, I'd say diet and nutrition are key. ... One glass of milk has 300 milligrams of calcium and one yogurt has 300. ... So, if you have both of those you're already meeting half of the 1,200-milligram-a-day requirement. Then, I'd add, watch your caffeine intake — which can leach both calcium and vitamin D. Try limiting yourself to three cups of coffee a day. Excessive alcohol and smoking should be avoided, as they can also lead to weakening of the bones. And exercise, of course.
Latest Health
Q: What about exercise?
A: Weight-bearing exercises are very beneficial ... walking, hiking, jogging, running, low-impact aerobics and dancing. For people with osteoarthritis, low-impact aerobics — such as an elliptical machine or Pilates — will help.
Q: I am guilty of mainlining Diet Coke because it satisfied my sweet tooth and I'm convinced its a better vice than eating cakes and cookies. Will I pay a price when I'm older?
A: That's a tough one. Moderation is the key to everything.


text:
Family Room
Room Details
We have put together amazingly luxurious rooms, giving you ample space to ensure your comfort. Fitted with all the necessary requirements listed to make your stay as easy as possible.
Room features
- Double Bed
- Free Internet
- Air Conditioned
- Bar Fridge
- Coffee & Tea
- 2 persons
- Double Bed
- Free Internet
- Flat Screen TV
- En-suite Bathroom (Hot Water)


text:
Sauvignon Blanc
Sauvignon Blanc has a special place in our hearts, since we produce a lone label from our Yountville vineyard. Crisp and refreshing with passion fruit and apricot, it is a great way to start a party or meal. Producers use stainless steel or oak to ferment. Some winemakers use Semillon to add a floral roundness to the wine.


text:
Note: See the AFP Journal Club Toolkit and MDCalc's glossary of EBM terms(www.mdcalc.com) for additional information on EBM terms and types of studies.
Select a Glossary:
Search terms alphabetically:
Unintentional bias is the result of using a weaker study design (e.g., a case series or observational study), not designing a study well (e.g., using too low a dose of the comparator drug), or not executing the study well (e.g., making it possible for participants or researchers to determine to which group they are assigned). Intentional bias also exists. Examples of study techniques that are designed to make a favorable result for the study drug more likely include a run-in phase using the active drug to identify compliant patients who tolerate the drug; per protocol rather than intention-to-treat analysis; and intentionally choosing too low a dose of the comparator drug or choosing an ineffective comparator drug.
Allocation concealment recently has been recognized as an important element of randomized controlled trial design. Allocation is concealed when neither the participants nor the researchers know or can predict to which group in a study (control or treatment) the patient is assigned. Allocation concealment takes place before the study begins, as patients are being assigned. Blinding or masking—concealing the study group assignment from those participating in the study—occurs after the study begins. Blinding should involve the patient, the physicians caring for the patient, and the researcher. It is particularly important that the persons assessing outcomes also are blinded to the patient's study group assignment.
Individual findings from the history and physical examination often are not helpful in making a diagnosis. Usually, the physician has to consider the results of several findings as the probability of disease is revised. Clinical decision rules help make this process more objective, accurate, and consistent by identifying the best predictors of disease and combining them in a simple way to rule in or rule out a given condition. Examples include the Strep Score, the Ottawa Ankle Rules, scores for ruling out pulmonary embolism, and a variety of clinical rules to evaluate perioperative risk. Also see this Point-of Care-Guide clinical decision rule table.
In a large study, a small difference may be statistically significant but not necessarily clinically significant. For example, does a 1- or 2-point difference on a 100-point dementia scale matter to your patients? It is important to ask whether statistically significant differences also are clinically significant. Conversely, if a study finds no difference, it is important to ask whether it was large enough to detect a clinically important difference and if a difference actually existed. A study with too few patients is said to lack the power to detect a difference.
The P value tells us how likely it is that the difference between groups occurred by chance rather than because of an effect of treatment. For example, if the absolute risk reduction was 4% with P = .04, if the study were done 100 times, a risk reduction this large would occur four times by chance alone. The confidence interval gives a range and is more clinically useful. A 95% confidence interval indicates that if the study were repeated 100 times, the study results would fall within this interval 95 times. For example, if a study found that a test was 80% specific with a 95% confidence interval of 74% to 85%, the specificity would fall between 74% and 85% 95 times if the study were repeated 100 times. In general, larger studies provide more precise estimates.
Disease-oriented evidence refers to the outcomes of studies that measure physiologic or surrogate markers of health. This would include things such as blood pressure, serum creatinine, glycohemoglobin, sensitivity and specificity, or peak flow. Improvements in these outcomes do not always lead to improvements in patient-oriented outcomes such as symptoms, morbidity, quality of life, or mortality.
External validity is the extent to which results of a study can be generalized to other persons in other settings, with various conditions, especially "real world" circumstances. Internal validity is the extent to which a study measures what it is supposed to measure, and to which the results of a study can be attributed to the intervention of interest, rather than a flaw in the research design. In other words, the degree to which one can draw valid conclusions about the causal effects of one variable or another.
People who volunteer for a clinical trial are generally healthier and have more favorable outcomes than those who do not. For example, when comparing English women who volunteered for a mammography trial with those who did not, the volunteers had half the overall mortality of those who stayed home. This is especially important in observational (nonrandomized) studies, and may lead to better outcomes than expected in those who volunteer to participate or choose to take a medicine or choose to exercise.
Were the participants analyzed in the groups to which they were assigned originally? This addresses what happens to participants in a study. Some participants might drop out because of adverse effects, have a change of therapy or receive additional therapy, move out of town, leave the study for a variety of reasons, or die. To minimize the possibility of bias in favor of either treatment, researchers should analyze participants based on their original treatment assignment regardless of what happens afterward. The intention-to-treat approach is conservative; if there is still a difference, the result is stronger and more likely to be because of the treatment. Per protocol analysis, which only analyzes the results for participants who complete the study, is more likely to be biased in favor of the active treatment.
When one screens for cancer, one will always detect cancers earlier. However, screening is only beneficial if the overall length of life increases, not just the time from diagnosis. Lead time is the time between detection of disease due to screening and when it would ordinarily be detected due to signs or symptoms. Lead time bias represents the apparent benefit that screening might seem to provide, but which actually just represents a longer duration of known disease, but no increase in actual lifespan. For a graphic representation of lead time bias, see figure 2 in Screening for Cancer: Concepts and Controversies.
In a study of cancer screening, a screening test is more likely to identify slower growing tumors than fast growing tumors, which may appear between screening intervals. In an observational study comparing screened with unscreened patients, this will make the outcomes appear better in the screening group, because the cancers detected have a more favorable prognosis. For a graphic representation of length time bias, see figure 3 in Screening for Cancer: Concepts and Controversies.
Likelihood ratios (LRs) correspond to the clinical impression of how well a test rules in or rules out a given disease. A test with a single cutoff for abnormal will have two LRs, one for a positive test (LR+) and one for a negative test (LR–). Tests with multiple cutoffs (i.e., very low, low, normal, high, very high) can have a different LR for each range of results. A test with an LR of 1.0 indicates that it does not change the probability of disease. The higher above 1 the LR is, the better it rules in disease (an LR greater than 10 is considered good). Conversely, the lower the LR is below 1, the better the test result rules out disease (an LR less than 0.1 is considered good).
Note: for additional information about likelihood ratios, see this comprehensive handout(3 page PDF).
The Choosing Wisely campaign has highlighted what it describes as low value care. That is, care which costs money and may even be harmful, but has not been shown to improve health outcomes in a clinically meaningful way compared with less costly or less potentially harmful alternatives. For example, screening EKGs in patients at low risk of coronary artery disease does not improve outcomes or cardiovascular risk prediction over traditional risk factors.
A network meta-analysis (also known as a multiple-treatments meta-analysis) allows you to compare treatments directly (for example, head-to-head trials) and indirectly (for example, against a first-line treatment). This increases the number of comparisons available and may allow the development of decision tools for effective treatment prioritization.
In the past, most randomized trials were designed to prove that one intervention was more effective than another. Non-inferiority trials are designed to prove that a (usually new) intervention is not significantly worse than another. It is important to carefully examine the assumptions about what is significantly worse and what is not.
The absolute risk reduction (ARR) can be used to calculate the number needed to treat, which is … number of patients who need to be treated to prevent one additional bad outcome. For example, if the annual mortality is 20% in the control group and 10% in the treatment group, then the ARR is 10% (20 – 10), and the number needed to treat is 100% ÷ ARR (100 ÷ 10) = 10 per year. That is, for every 10 patients who are treated for one year, one additional death is prevented. The same calculation can be made for harmful events. The number of patients who need to receive an intervention instead of the alternative for one additional patient to experience an adverse event. The NNH is calculated as: 1/ARI, where ARI is absolute risk increase (see NNT). For example, if a drug causes serious bleeding in 2% of patients in the treatment group over one year compared with 1% in the control group, the number needed to treat to harm is 100% ÷ (2% – 1%) = 100 per one year. The absolute increase (ARI) is 1%.
In an observational study of a drug or other treatment, the patient chooses whether or not to take the drug or to have the surgery being studied. This may introduce unintentional bias. For example, patients who choose to take hormone therapy probably are different from those who do not. Experimental studies, most commonly randomized controlled trials (RCTs), avoid this bias by randomly assigning patients to groups. The only difference between groups in a well-designed RCT is the treatment intervention, so it is more likely that differences between groups are caused by the treatment. When good observational studies disagree with good RCTs, the RCT should be trusted.
Observational studies usually report their results as odds ratios or relative risks. Both are measures of the size of an association between an exposure (e.g., smoking, use of a medication) and a disease or death. A relative risk of 1.0 indicates that the exposure does not change the risk of disease. A relative risk of 1.75 indicates that patients with the exposure are 1.75 times more likely to develop the disease or have a 75% higher risk of disease. Odds ratios are a way to estimate relative risks in case-control studies, when the relative risks cannot be calculated specifically. Although it is accurate when the disease is rare, the approximation is not as good when the disease is common.
Overdiagnosis occurs when a screening test detects a condition that is typically treated, but that in this case never would have become clinically apparent or caused symptoms. For example, screening with PSA often detects prostate cancers that are treated, but that never would have progressed to cause symptoms prior to death from another cause. For a graphic representation of overdiagnosis bias, see figure 4 in Screening for Cancer: Concepts and Controversies.
Overtreatment refers to treating when it is not indicated, or treating more aggressively than is warranted. For example, targeting a blood pressure of 120/80 in an average risk person or using antibiotics for acute bronchitis.
Patient-oriented evidence (POE) refers to outcomes of studies that measure things a patient would care about, such as improvement in symptoms, morbidity, quality of life, cost, length of stay, or mortality. Essentially, POE indicates whether use of the treatment or test in question helped a patient live a longer or better life. Any POE that would change practice is a POEM (patient-oriented evidence that matters).
Simple randomization does not guarantee balance in numbers during a trial. If patient characteristics change with time, early imbalances cannot be corrected. Permuted block randomization ensures balance over time. The basic idea is to randomize each block such that m patients are allocated to A and m to B.
Predictive values help interpret the results of tests in the clinical setting. The positive predictive value (PV+) is the percentage of patients with a positive or abnormal test who have the disease in question. The negative predictive value (PV–) is the percentage of patients with a negative or normal test who do not have the disease in question. Although the sensitivity and specificity of a test do not change as the overall likelihood of disease changes in a population, the predictive value does change. For example, the PV+ increases as the overall probability of disease increases, so a test that has a PV+ of 30% when disease is rare may have a PV+ of 90% when it is common. Similarly, the PV changes with a physician's clinical suspicion that a disease is or is not present in a given patient.
Whenever an illness is suspected, physicians should begin with an estimate of how likely it is that the patient has the disease. This estimate is the pretest probability. After the patient has been interviewed and examined, the results of the clinical examination are used to revise this probability upward or downward to determine the post-test probability. Although usually implicit, this process can be made more explicit using results from epidemiologic studies, knowledge of the accuracy of tests, and Bayes' theorem. The post-test probability from the clinical examination then becomes the starting point when ordering diagnostic tests or imaging studies and becomes a new pretest probability. After the results are reviewed, the probability of disease is revised again to determine the final post-test probability of disease.
A receiver operating characteristic (ROC) curve plots the true positive rate (percent of patients with disease who have a positive test) against the false positive rate (percent without disease who have a positive test) as one varies the cutoff for what defines a positive test. The area under this curve is 1.0 for a perfectly accurate test, and 0.5 for a useless test, with higher values representing more accurate tests. The area under the ROC curve also corresponds to the likelihood that the test will correctly classify two randomly selected people correctly, one with and one without disease. The ROC curve below is for vaginal ultrasound as a test for uterine cancer, using different cutoffs for endometrial wall thickness as abnormal.
Note: the "mm" values in this graph represent endometrial wall thickness, as observed on ultrasound.
Studies often use relative risk reduction to describe results. For example, if mortality is 20% in the control group and 10% in the treatment group, there is a 50% relative risk reduction ([20 – 10] ÷ 20) x 100%. However, if mortality is 2% in the control group and 1% in the treatment group, this also indicates a 50% relative risk reduction, although it is a different clinical scenario. Absolute risk reduction subtracts the event rates in the control and treatment groups. In the first example, the absolute risk reduction is 10%, and in the second example it is 1%. Reporting absolute risk reduction is a less dramatic but more clinically meaningful way to convey results.
A run-in period is a brief period at the beginning of a trial before the intervention is applied. In some cases, run-in periods are appropriate (for example, to wean patients from a previously prescribed medication). However, run-in periods to assess compliance and ensure treatment responsiveness create a bias in favor of the treatment and reduce generalizability.
The number of patients in a study, called the sample size, determines how precisely a research question can be answered. There are two potential problems related to sample size. A large study can give a precise estimate of effect and find small differences between groups that are statistically significant, but that may not be clinically meaningful. On the other hand, a small study might not find a difference between groups (even though such a difference may actually exist and may be clinically meaningful) because it lacks statistical power. The "power" of a study takes various factors into consideration, such as sample size, to estimate the likelihood that the study will detect true differences between two groups.
Sensitivity is the percentage of patients with a disease who have a positive test for the disease in question. Specificity is the percentage of patients without the disease who have a negative test. Because it is unknown if the patient has the disease when the tests are ordered, sensitivity and specificity are of limited value. They are most valuable when very high (greater than 95%). A highly Sensitive test that is Negative tends to rule Out the disease (SnNOut), and a highly Specific test that is Positive tends to rule In the disease (SpPIn).
Also known as Cohen's d, the standardized mean difference (SMD) is used to combine the results from studies using scales that have different lengths or sizes but are attempting to measure the same underlying parameter. For example, the 30-point Mini-Mental State Examination score and the 72-point Alzheimer's Disease Assessment Scale–cog score are both measures of the severity of cognitive impairment. The SMD is calculated as the difference in the mean outcome between groups divided by the standard deviation. In general, an SMD less than 0.2 is not clinically significant, an SMD of 0.2 represents a small clinical effect, an SMD of 0.5 is a moderate effect, and an SMD of 0.8 or greater is a large effect.
Often, there are many studies of varying quality and size that address a clinical question. Systematic reviews can help evaluate the studies by posing a focused clinical question, identifying every relevant study in the literature, evaluating the quality of these studies by using predetermined criteria, and answering the question based on the best available evidence. Meta-analyses combine data from different studies; this should be done only if the studies were of good quality and were reasonably homogeneous (i.e., most had generally similar characteristics).
A visual analog scale asks participants to rate pain or some other subjective outcome on a scale, typically ranging from 0 to 100 points, where 0 is no pain and 100 is the worst possible pain imaginable. A difference of at least 10 points is the smallest change that is clinically noticeable or significant. Smaller differences may be statistically significant but are unlikely to be noticeable by patients.
Studies of treatments, whether the treatment is a drug, device, or other intervention, must be randomized controlled trials. Because most new, relevant medical information involves advances in treatment, these studies must sustain rigorous review.
Validity questions
Studies of diagnostic tests, whether in a laboratory or as part of the physical examination, must demonstrate that the test is accurate at identifying the disease when it is present, that the test does not identify the disease when it is not present, and that it works well over a wide spectrum of patients with and without the disease.
Only systematic reviews (overviews), including meta-analyses, will be considered.
The main threats to studies of prognosis are initial patient identification and loss of follow-up. Only prognosis studies that identify patients before they have the outcome of importance and follow up with at least 80 percent of patients are included.
Decision analysis involves choosing an action after formally and logically weighing the risks and benefits of the alternatives. Although all clinical decisions are made under conditions of uncertainty, this uncertainty decreases when the medical literature includes directly relevant, valid evidence. When the published evidence is scant, or less valid, uncertainty increases. Decision analysis allows physicians to compare the expected consequences of pursuing different strategies under conditions of uncertainty. In a sense, decision analysis is an attempt to construct POEMs artificially out of disease-oriented evidence.
Qualitative research uses nonquantitative methods to answer questions. While this type of research is able to investigate questions that quantitative research cannot, it is at risk for bias and error on the part of the researcher. Qualitative research findings will be reported if they are highly relevant, although specific conclusions will not be drawn from the results.
These are a broadly accepted set of nine criteria to establish causality between an exposure or incidence and an effect or consequence. In general, the more criteria that are met, the more likely the relationship is causal.
Information from Hill AB. The environment and disease: association or causation? Proc R Soc Med. 1965;58(5):295-300.
EBM Features and Departments
AFP Journal Club Toolkit »
Share this page
This page will be removed from your Favorites Links. Are you sure?
AFP Home
EBM Toolkit
EBM Glossaries


text:
- Font:
- +
- -
With the Lady Gaga-market reaching oversaturation, it's easy to get a sense of fatigue when listening to her latest effort, "Born This Way."
Delivering her third studio album in just a 3-year span after a nonstop juggernaut that included a seemingly endless tour, hit after hit, countless magazine covers and even social activism, another Gaga offering is a little bit tiring to those who aren't part of her army of "little monsters."
It doesn't help that the standard edition of the album is 17 full-length tracks, clocking in at a little over two hours. A little less than a third of the way through, a "what — there's more?" feeling starts to sink in, and finishing the album seems to be a daunting task.Slideshow: Fashion gone Gaga (on this page)
More Entertainment stories
Autistic ballerina dances her way into hearts
In a popular YouTube video, the beaming little ballerina dances an entire four-minute routine seemingly perfectly, matchin...
- Every on-screen drink in 'Mad Men' in 5 minutes
- See the 'Dancing' stars' most memorable moves
- Emmy's biggest snubs? Cranston, Hamm, more
- 'Toy Story' toys burn up in prank on mom
- Autistic ballerina dances her way into hearts
But "Born This Way" deserves that listen — again and again and again. Though there are a few songs that miss the mark — the Madonna-rip-off title track, for example — overall, the album, like Gaga, is hard to get out of your conscious.
"I could be girl/ unless you want to be man/ I could be sex/ unless you want to hold hands/ I could be anything/ I could be everything," coos Gaga on "Government Hooker," a wicked electro-groove that manages to be more naughty than Rihanna's "S&M" without being as explicit. It's just part of the provocation — both sexual and religious — that Gaga uses to push buttons throughout the album.
Though there are song titles like "Bloody Mary," "Judas" and "Electric Chapel," and lyrics tweak conservative mindsets, at its core, "Born This Way" is mostly an album about themes that have been written about from the beginning of pop music — love, lust and acceptance.Story: Lady Gaga album demand overwhelms Amazon servers
"Americano," with its flamenco-inspired melody, is a love song — it just happens to be about two women. "We can marry, on the West Coast, on a Wednesday," Gaga sings slyly. "Hair," like "Born This Way," is a plea for individual freedom via the follicles — "I don't want to change, I don't want to be ashamed, I'm the spirit of my hair ... I am my hair," she declares on the pop-rock groove, which sounds as if it could have emerged from the soundtrack to a 1980s teen flick.
Much of the music veers from pulsating dance grooves and the retro rock that Gaga showcased on "Fame Monster." The album's best track —"You and I" — sounds as if it could be the companion to "Speechless," another ballad similarly anchored by dominating piano chords.
Gaga, who co-wrote every tune on the record and again worked with collaborators such as RedOne and Fernando Garibay, doesn't show particular musical growth, but establishes a consistency of strong material throughout most of the disc. Lyrically, at times she still perplexes — the whirring "ScheiBe" starts off with German then segues into a female empowerment anthem — but it's those bizarre moments that are part of the Gaga-intrigue.
"Born This Way" needs a bit more editing. A smattering of tracks, like "Bad Kids" or "Black Jesus," could have been left off for a tighter disc. But it doesn't take away from its strength, and overall, it's an album that should add to Gaga's growing status as this generation's cultural icon.
CHECK OUT THIS TRACK: Most won't know what she's saying, and most won't care, on "ScheiBe" — the German (or is it gibberish?) that comes out of Gaga's mouth is still undeniably catchy.
Copyright 2011 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.


text:
One glimpse of the police motorcade, and I flashed back to my DC days …
As a student at Howard University, I spent five years in the Nation's capital. A Presidential parade was nothing new to me. Although the eyes of the Nation were focused on my hometown, I was more concerned with simply going home.
I closed my books and came out of Oakland's main library: Hungry. Frustrated. Feeling pissed. Plus I had to piss…
"If all these badge rockin' overseers (officers) weren't around- I'd water this shrub." I remember thinking to myself as I copped a squat next to a bush. The police wouldn't let me cross the street; they told me that the President would be passing in ten minutes… My thoughts began to race, so I held my bladder, and blasted off a couple of tweets:
"If i pass this class, I can save myself. If I save myself, I can save my people"
"… No matter what the President does… "
"(I'm sitting next to a bush, tweeting… surrounded by policemen.)"
If I pass this test I can graduate undergrad. If I graduate undergrad, I can start grad school. When I finish grad school, as a professional journalist with a teacher's degree, I will be able to access and allocate resources that we all can use to better our community.
In the grand scheme of things the, Presidential election does matter. I know it does.
Do I have any voice in that matter- honestly, I don't know. I know- 1 vote, 1 person. I know the electoral college. I know that large "Political Action Committees" are BIG sponsors of campaigns. I also understand that there is a lot that I don't know.
I understand that there is a Black man in the most powerful office of all of the land… I understand that very clearly…
But I've only seen that via media. And I don't always believe the media… especially media about the government.
In person, I've seen some things:
In September of 2008, I was in Denver for the Democratic National Convention.
In November of 2008 when the news was announced that Senator Obama had been elected as President of the United States of America, I was on Howard University's campus in Washington DC.
I was even in Nation's Capital on the frosty morning of January 20, 2009 during the inaugural celebration of America's first African-American President.
I saw it. I didn't understand it. But I saw it.
I didn't vote in the 2008 election… I know, I know…
I support the image of a Black man in the Oval Office, it speaks volumes as to how far this country has come. But the politics behind it- I still question. I figure I fall into the fray, full of Black folks who feel the same way; untrusting of our government. Untrusting is an understatement…
Look man, I'm coming from Oakland, Ca. A place where people have seen the underhandedness of local governing bodies time and time again. In the past four years- we've seen blatant dirt on the hands of the State (CA budget) , the City (Police), and even the Transit cops (Oscar Grant). To think that the Federal Government- will do something to better the situation in our Oakland neighborhood is behooving, farfetched, and unrealistic to many of us out here.
Well, recently… the Federal Government has done SOMETHING to aid the city The NY Times ranked as "the World's 5th best tourist attraction of 2012"…
On the same morning that the Federal forces made a move to close Oakland's famed medical marijuana college… a mass shooting occurred at Oikos University, a small Christian school located in East Oakland. Unfortunately fittingly.
There are people in this city struggling to make ends meet, losing lives to gun violence (with both policemen and black/brown men behind the trigger), and people who have been scarred by the woes of the world. These are the people who don't trust in the government. On any level.
The 99%er movement, which swept the Nation in October/ November of 2011, took to a different feel here in Oakland. Protesters of all backgrounds combined forces and claimed residency right under Oakland's main tree- in the center of the city. The local governing officials didn't take too kind it's new neighbors, and eventually gave them an eviction notice… in the form of a sunrise police raid. The raid set off a domino effect of rebellious actions on the part of the people- and eventually ended with many reports condemning the City of Oakland's approach to the Occupy situation.
The remnants of this movement are still felt locally, as spray paint still adorns the side local businesses and the grass on the City of Oakland lawn is still patchy and brown. Nationally, the Occupy Movement in Oakland is still ringing bells, hence this NY Times Article published on Aug 1st, 2012.
President Obama's late July appearance in Oakland was greeted by protesters… per usual. Many of the protesters were fighting global injustices, federal wrong-doings, and for the legalization of medical marijuana… And some protesters were just out there to protest, as many do in this city.
While protesters, fans, and police motorcades focused on President Obama being in town, three notable events occurred in Oakland:
1. An investigation was ongoing after a weekend shooting in East Oakland left a 5-year old girl in the hospital.
2. A two-day incident, which initially began as a high speed chase and eventually concluded in a house in East Oakland where a standoff between armed men and police lasted 12 hours.
3. The family of Alan Blueford, a teenager who was shot by OPD, filed a federal civil rights lawsuit against the City of Oakland. Blueford was killed on May 6th. The officer who shot, also shot himself in the foot. The officer's name has not been released, neither has Blueford's autopsy records. Therefore, the family cannot move forward with this case.
These are the problems that haunt this town. Local issues. These are the issues I find myself concerned with. Local issues … not National issues.
The people of my city are children who have been hurt by miscellaneous happenings, sisters who have been scarred by society, and people… hurt people.
Just imagine: If cured, what wonders could these people do to change society?
One week after President Obama's visit to Oakland, an article about the nature and nurture of Black men in Oakland was published in a local newspaper. The very next day, the NY Times again chose to shine light on America's new tourist attraction: Oakland, Ca.
How can we open our doors to the world, if our house isn't clean?
What is the significance of President Obama leaving the white house, to come to a town where Black and Brown people die in the street- before and after he leaves?
I've done a little research; now, I'm sure I could stand to do some more, but this is what I've concluded:
I- a young man who watched the 2008 Presidential election process with a lazy eye, a young man who has watched the little (if any) "change" in my local neighborhood with a hawk's eye, and a young man who is going to the University of California's graduate school of journalism this fall… I have a responsibility.
Outside of individual donors, the University of California Berkeley was noted as the biggest contributor to Barack Obama's 2008 Presidential campaign, and the Golden Bears are among the leading contributors to President Obama's 2012 campaign thus far.
I need to pay more attention to the connection between the local issues and the federal/ National implications of these issues…For my voice does matter.
And, if I can take it upon myself to broaden my focus, I'm sure the people in power locally can take their mind off of federal/ national issues to deal with hometown matters.
I'd be willing to make a deal.
My curbside treehouse was prime real estate for these ruminations. I emerged from my thoughts just in time to take a photo of the Presidential parade as they made their way through the East Bay.
Ten minutes passed, Presidential Lincolns passed. Remaining true to their word- the officers then said I could pass. I went home, urinated, and studied some more. I've got a class to pass.


text: From User talk:Phanect If you look at http://techbase.kde.org/Special:PageTranslation, at the bottom you will see a list of KDE3 pages marked for translation. Are translations needed, or would it be better to remove them from the Translate system? I'd like your opiion, please. MoreHistory View source Link toAnnew 09:37, 10 June 2012 It means that all translations are removed, right? I'll discuss with Japanese-speaking community about how to process KDE 3 documents on kde.gr.jp wiki, so can you wait for some days? Parent MoreHistory View source Link toPhanect 07:50, 11 June 2012 I asked a SLAX-ja project organizer. SLAX is a distribution which use Trinity Desktop. He said he need those KDE 3 documents, so I'll consider solution. Parent MoreHistory View source Link toPhanect 08:52, 11 June 2012 What I was proposing would not have removed the existing translations, but they would not have been listed for further work. For the moment we are not proposing to remove any KDE3 pages. When we do feel that we need to, we will not delete them, but move them to Archive:pagename so they will still be available when needed. My rationale for asking the question is that it seems unlikely that changes, and therefore new versions of translation, would be needed on the KDE3 pages. However, it's important not to make things difficult for any group of users, so I'll wait to hear what the Trinity Desktop people need. This is not something urgent :-) Parent MoreHistory View source Link toAnnew 15:10, 11 June 2012 > we will not delete them, but move them to Archive:pagename so they will still be available when needed. Oh, I see. So there is almost no problem. Is it possible to add translation for archived articles? There are still some translations of KDE3 on .jp wiki, so I'd like to merge them. Parent MoreHistory View source Link toPhanect 16:53, 12 June 2012 I'd like to take them out of the translate system, make them set in stone, but that situation definitely calls for a stay of execution.Please carry on working with them, and if you hit any problems let me know. I'll try to resolve them. Once you feel that everything is adequately covered we'll archive the pages, keeping them intact. Parent MoreHistory View source Link toAnnew 17:40, 12 June 2012 OK. I'll continue to work on. Thanks :) Can I add translation in old way? (Create page named "***_(ja)") With current translation system, it takes time to merge because I have to check each sentences. (Not all Japanese translations are up to date. Some sentences are added or removed from English version.) Parent MoreHistory View source Link toPhanect 06:39, 13 June 2012 You could do that, but please remind me, when you are finished, that those pages need to be archived manually. I'll do it, but my memory is horribly bad. It occurs to me that the reason this thread was started was that some ...(ja) pages had translate tags. I you add the <translate></translate> pair, top and bottom of the page, it should get listed with those others. That should help us remember which ones are to be archived. Parent MoreHistory View source Link toAnnew 09:54, 13 June 2012 All right. I'll copy & paste Japanese translation from .jp wiki to ..._(ja) page of techbase. You don't mean that I have to add <translation> tags on ..._(ja) page and/or original English page, right? Let me ask to avoid misunderstanding... Parent MoreHistory View source Link toPhanect 10:34, 13 June 2012 I'm thinking aloud, and it may not work, but I'm suggesting that we put it onto the Japanese pages. It's nonsensical to be there, which should remind me that I have to manually deal with them. If you have any better ideas I don't mind - I just want something to remind me :-) It won't actually cause them to be in the translation system, as someone (usually me) has to mark them ready for translation. Parent MoreHistory View source Link toAnnew 12:36, 13 June 2012 OK. I thought it is natural to put translations near the original pages, but it is also OK to put on .jp server. Parent MoreHistory View source Link toPhanect 15:04, 13 June 2012 Retrieved from "https://techbase.kde.org/Thread:User_talk:Phanect/KDE3_pages#KDE3_pages_135"


text:
Pros Day
All the information you need regarding the upcoming Pro's Day. Read more.......
All the information you need regarding the upcoming Pro's Day. Read more.......
My Poll
Thanks for voting!
Here are the current poll results
Glenmuir Talia Winter Trouserview other products
With their fleece backing, you'll find these comfortable ladies trousers are ideal for golfing during the colder months.
The Glenmuir Talia trousers have been specifically designed with a fleece backing for warmth and using a 13% elastane construction so they can stretch for enhanced walking and swinging comfort.
Key features include:
- Part-elastane fabric for enhanced range of motion
- Fleece backing for additional warmth
- Available in waist sizes from 8-18
- Short, regular and long leg lengths
Swing by the shop and try on a pair of these super-comfortable thermal trousers. You'll find them ideal for tackling autumn and winter golf.


text:
Associated Press
NEW CASTLE, DEL.: A small plane crashed in a marshy area in New Jersey near the Delaware River shortly after takeoff from an airport in Delaware Saturday, officials said. The pilot and his passenger both survived.
The Federal Aviation Administration was investigating after the Cessna 172 crashed in a marsh about five miles southeast of New Castle Airport at about 10:40 a.m. The pilot had reported engine problems before the crash, the FAA said.
Delaware State Police say two people were rescued from the single-engine plane and didn�t appear to have life-threatening injuries.
The plane was located in an area between Fort Delaware State Park and Fort Mott State Park in New Jersey, with the plane�s occupants seen near the aircraft. A helicopter was able to get the two occupants from the water.
Pennsville Police Lt. Kirk Cooksey told the South Jersey Times that both men are in their late 70s and are from the West Chester, Pennsylvania, area.
�I consider them very lucky that they walked away from that,� he said.
Cooksey said that the plane was mired in deep mud in an area that is difficult to access.
�How are we going to get the plane out? I don�t know,� he said.


text:
Pre-Surgery Lily
May 23, 2011
She's going to the vet for surgery this evening and I'm FREAKING OUT (Yes, I know my grin is deceiving). Worst case scenarios are running through my head and every time I'm on the verge of tears. I try to distract myself but keep on thinking what if, what if, what if.
I'm hugging the crap out of her while I can, I drop her off in a few minutes.
Please send her virtual hugs and kisses!
A proper post is coming soon, I need to get her prepped and ready 😦
3 Comments leave one →


text:
Western blot analysis of extracts from NIH/3T3 cells, transfected with 100 nM SignalSilence® Control siRNA (Unconjugated) #6568 (-) or SignalSilence® CK2α siRNA I (Rodent Specific) (+), using CK2α Antibody #2656 (upper) or β-Actin (D6A8) Rabbit mAb #8457 (lower). The CK2α Antibody confirms silencing of CK2α expression, while the β-Actin (D6A8) Rabbit mAb is used as a loading control.
Product Information
CST recommends transfection with 100 nM SignalSilence® CK2α siRNA I (Rodent Specific) 48 to 72 hours prior to cell lysis. For transfection procedure, follow protocol provided by the transfection reagent manufacturer. Please feel free to contact CST with any questions on use.
Each vial contains the equivalent of 100 transfections, which corresponds to a final siRNA concentration of 100 nM per transfection in a 24-well plate with a total volume of 300 μl per well.
SignalSilence® siRNA is supplied in RNAse-free water. Aliquot and store at -20ºC.
SignalSilence® CK2α siRNA I (Rodent Specific) from Cell Signaling Technology (CST) allows the researcher to specifically inhibit CK2α expression using RNA interference, a method whereby gene expression can be selectively silenced through the delivery of double stranded RNA molecules into the cell. All SignalSilence® siRNA products from CST are rigorously tested in-house and have been shown to reduce target protein expression by western analysis.
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
CK2 (formerly called Casein Kinase II) is a highly conserved protein kinase with more than 300 substrates regulating cell growth, cell death, and cell survival. CK2 has been implicated in the response to UV irradiation-induced DNA damage, targeting XRCC1 (1) and BRCA1 (2) as well as regulating p53 tumor suppressor protein functions (3). Furthermore, CK2 plays a key role in NF-κB activation (4). UV irradiation stimulates CK2-mediated phosphorylation of several carboxy-terminal residues within IκBα, resulting in IκBα proteasomal degradation and the release and nuclear translocation of active NF-κB. CK2 is also dysregulated in many cancers (5) and neurodegenerative diseases such as Alzheimer's and Parkinson's diseases (6). Structurally, CK2 is a multimeric protein complex consisting of two catalytic subunits (α or α') and two regulatory β subunits (7). CK2 is distributed ubiquitously and is apparently constitutively active (7). While cell cycle-dependent Ser-Pro phosphorylation sites have been identified on CK2α and CK2β, Tyr255 phosphorylation by the Src-related kinase c-Fgr seems to have the greatest effect on CK2α activity (8,9).
Explore pathways + proteins related to this product.
UniProt ID: Q60737
Entrez-Gene Id: 12995
|Product #
|300 µl (3 nmol)
|$ 270


text:
Tomorrow is Bastille Day. Everyone should be watching stage 10 of the Tour de France. Special shout out to all the french riders…like Sandy Casar who won today in stage 9, Christophe Moreau, Jérôme Pineau and John Gadret.
Some insight to today's stage in the Alps from the NY Time's tour corespondent, Juliet Macur.